Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...
FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.
FDA Expands Approval for Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria
Pediatric approval leveraged CupidKids pharmacokinetic bridging assessments, with adverse events consistent across ...
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...
Proportion of patients with complete response (UAS7=0).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results